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This editorial refers to ‘One-year clinical outcomes with
abciximab vs. placebo in patients with non-ST-segment
elevation acute coronary syndromes undergoing percuta-
neous coronary intervention after pre-treatment with
clopidrogel: results of the ISAR-REACT-2 randomized
trial’ by G. Ndrepepa et al.,† on page 455
The second Intracoronary Stenting and Antithrombotic Regimen:
Rapid Early Action for Coronary Treatment (ISAR-REACT-2)
study randomized 2022 high-risk patients with non-ST-segment
elevation acute coronary syndromes (ACS) undergoing percuta-
neous coronary intervention (PCI) to receive abciximab or
placebo in addition to aspirin and clopidogrel 600 mg loading
dose administered at least 2 h prior to the procedure. All patients
received periprocedural unfractionated heparin. The incidence of
the primary end-point of the study—the composite of death, myo-
cardial infarction (MI), or urgent target vessel revascularization
(TVR) at 30 days—was significantly reduced by 25% in the abcix-
imab group.1 No difference was observed in terms of major or
minor bleeding events between treatment assignments. In the
present issue of the journal, Ndrepepa et al. have demonstrated
that a statistically significant benefit is maintained at 1 year, with
a 20% reduction in the rate of death, MI, or TVR, and a 25%
reduction in death or MI among patients allocated to abciximab.2
Despite the positive results, it seems unlikely that these findings
will translate into an increase in the prescription of platelet glyco-
protein IIb/IIIa receptor inhibitors (GP IIb/IIIa inhibitors). The use of
this drug class has declined substantially since the advent of clopi-
dogrel, and now GP IIb/IIIa blockers have to compete with newer
antithrombotic and antiplatelet agents such as bivalirudin, fonda-
parinux, and prasugrel.
The GP IIb/IIIa receptor—or aIIB/b3 integrin—is the most abun-
dant platelet membrane glycoprotein found in humans and is a key
mediator of thrombus formation. Following spontaneous rupture
of an atherosclerotic plaque or balloon catheter-mediated baro-
trauma of the vessel wall, the subendothelial matrix is exposed
to the blood circulation. Substances such as collagens, fibronectins,
and von Willebrand factor (vWF) are recognized by adhesion
receptors on the platelet surface and promote platelet adhesion
and activation. The hallmark of platelet activation is the confor-
mational changes of the GP IIb/IIIa receptor—with subsequent
transformation from a low- into a high-affinity state—allowing
for binding of fibrinogen and vWF.3 Although GP IIb/IIIa antagonists
achieve a greater degree of platelet aggregation inhibition than
aspirin or clopidogrel they do not affect platelet activation but pri-
marily inhibit platelet aggregation by competing with ligand binding,
a critical step for interplatelet bridging and aggregate formation.
The excitement that accompanied the launch of GP IIb/IIIa blockers
in the 1990s was based on the assumption that the inhibition of the
‘final common pathway’ of platelet aggregation would translate into
an improvement in prognosis of patients undergoing PCI or pre-
senting with ACS. Abciximab, the prototype of the GP IIb/IIIa
blockers, contributed much to the aura surrounding this drug
class. Key to success were the unmatched degree of platelet aggre-
gation inhibition achieved—approximately 95% at 5 min after intra-
venous bolus administration—and also the interest surrounding its
peculiar molecular structure—a fragment of a mouse–human chi-
meric monoclonal antibody.
The clinical testing phase started with the three EPI trials in
which abciximab was administered against placebo in patients
undergoing PCI. The studies included patients with stable and
unstable coronary disease. Stenting was performed in a minority
of patients, and ADP antagonists were administered only in
stented patients following the procedure.4 Subsequently, other
compounds of the same class—tirofiban, eptifibatide, and lamifi-
ban—entered randomized trial evaluation. The benefit associated
with the use of these agents was mainly in terms of reduction in
periprocedural MI, though from the very beginning a controversy
surrounded the clinical relevance of the differences observed in
post-procedural elevation of cardiac enzymes. With respect to
long-term benefit, a pooled analysis of the EPI trials reported
that the administration of abciximab was associated with a mor-
tality reduction at 4.8 years follow-up.3 The last GP IIb/IIIa inhibi-
tor–PCI trial performed without a systematic clopidogrel loading
dose prior to the procedure was the Enhanced Suppression of
the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT)
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study, in which allocation to the GP IIb/IIIa receptor inhibitor epti-
fibatide in a novel dosing (double bolus) was associated with a 35%
reduction in death, MI, or urgent TVR at 30 days among patients
undergoing coronary stenting.5 For the first time, approximately
half of the patients were pre-treated with a thienopyridine
(either ticlopidine or clopidogrel) in addition to aspirin.
In parallel to the PCI setting, the efficacy of GP IIb/IIIa inhibitors
was tested in the medical management of non-ST-segment
elevation ACS. Overall, the use of these agents resulted in a
modest benefit over placebo despite no use of clopidogrel,
namely a 9% relative reduction in death or MI at 30 days.6 In the
Global Utilization of Streptokinase and Tissue Plasminogen Activa-
tor for Occluded Coronary Arteries (GUSTO) IV study, abciximab
was even harmful if administered over a 48 h period.7 As a conse-
quence of insufficient efficacy, the compound lamifiban was aban-
doned. The confidence in GP IIb/IIIa inhibitors was further shaken
by the premature termination of clinical trials testing of prolonged
oral GP IIb/IIIa blockade post-ACS because of the increased mor-
tality rate in the active treatment arm.8 Although the underlying
mechanisms remain to be demonstrated, a prothrombotic state
associated with chronic insufficient platelet inhibition was
postulated.9
It has been difficult to integrate the results of GP IIb/IIIa studies
from the 1990s into a contemporary setting characterized by clo-
pidogrel loading, newer anticoagulants, and varying degrees of
patient acuity and risk/benefit. By means of three sequential ran-
domized trials, the group of Scho¨mig and Kastrati in Munich sys-
tematically addressed the issue of whether GP IIb/IIIa receptor
inhibitors conferred additional benefit in low-, medium-, and
finally high-risk patients undergoing PCI following optimal pre-
treatment with clopidogrel (i.e. with 600 mg at least 2 h prior to
the procedure). The ISAR-REACT study enrolled stable patients
and detected no benefit of GP IIb/IIIa blockade. The patients
enrolled were at low risk, with a death, MI, or urgent TVR rate
at 30 days of 4%.10 Subsequently, the same drug regimen was
tested in stable diabetic patients in the ISAR-SWEET study.
Although the study was underpowered, no benefit from abciximab
was detected.11 As reported above, ISAR-REACT-2—enrolling
high-risk ACS patients—demonstrated for the first time that the
administration of GP IIb/IIIa blockers was associated with a
reduction in ischaemic events in patients optimally pre-treated
with clopidogrel. At 30 days, a pre-specified analysis showed that
the significant benefit was confined to troponin-positive patients.
This is not surprising, since troponin-negative patients enrolled in
ISAR-REACT-2 had an event rate at 30 days comparable with
the overall population enrolled in the ISAR-REACT study.
The third field of GP IIb/IIIa inhibitor clinical trial testing included
patients with ST-elevation myocardial infarction (STEMI). The
largest trial, the Controlled Abciximab and Device Investigation
to Lower Late Angioplasty Complications (CADILLAC), did not
show a benefit of abciximab over placebo in patients undergoing
PCI.12 The study had the limitation that half of the patients did
not receive a stent and—more importantly—that randomization
occurred following coronary angiography. This resulted in the
enrolment of a low-risk population, as demonstrated by an
overall mortality rate of 1.4% at 30 days. Conversely, high-risk
patients enrolled in smaller STEMI trials derived a benefit in
terms of death or MI and death at 3 years.13 A meta-analysis
aiming to summarize the entire randomized experience on the
intravenous administration of GP IIb/IIIa receptor antagonists in
patients undergoing PCI identified 21 randomized trials for a
total of almost 24 000 patients.14 Allocation to GP IIb/IIIa blockers
was associated with a statistically significant mortality reduction of
28 and 20% at 30 days and 1 year, respectively. Minor but not
major bleedings were more common in the active treatment arm.
According to the 2005 ESC PCI guidelines, GP IIb/IIIa inhibitors
have a grade IIa recommendation for PCI in stable patients for
complex lesions, or as bailout for periprocedural complications,
and abciximab has the same recommendation for primary PCI.15
In the setting of ACS, a grade IIa recommendation is given for
these agents in the 2007 ESC guidelines for patients with inter-
mediate to high-risk status undergoing early coronary angiogra-
phy.16 From a practical perspective, even in the golden era of GP
IIb/IIIa blockers their global market share never surpassed 50%.
The best days for this class of drugs appear to be over, with a
rapidly shrinking proportion of patients who may derive incremen-
tal benefits from GP IIb/IIIa blockers. Accordingly, the broad use of
clopidogrel pre-loading and the availability of an alternative anti-
thrombotic regimen such as bivalirudin, fondaparinux, or prasugrel
will probably confine GP II/IIIa blockers to bailout therapy for peri-
procedural complications of PCI and to the treatment of high-risk
ACS patients, with or without ST-segment elevation.
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